{{Drugbox
| IUPAC_name = [(3''R'')-3-(prop-2-ynylamino)indan-5-yl]-''N''-propylcarbamate
| image = Ladostigil.svg
| width = 250

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 209349-27-4
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 208907
| ChemSpiderID = 181005
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SW3H1USR4Q
| KEGG = D03239

<!--Chemical data-->
| C=16 | H=20 | N=2 | O=2 
| molecular_weight = 272.34 g/mol
| synonyms = [''N''-propargyl-(3''R'')-aminoindan-5yl]-''N''-propylcarbamate
}}

'''Ladostigil''' ('''TV-3,326''') is a novel [[neuroprotective]] [[drug|agent]] being investigated for the treatment of [[neurodegenerative disorder]]s like [[Alzheimer's disease]], [[Lewy body disease]], and [[Parkinson's disease]].<ref name="pmid11205137">{{cite journal  |vauthors=Weinstock M, Bejar C, Wang RH, etal | title = TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease | journal = Journal of Neural Transmission. Supplementum | volume = | issue = 60 | pages = 157–69 | year = 2000 | pmid = 11205137 | doi = | url = }}</ref> It acts as a [[reversible inhibition|reversible]] [[acetylcholinesterase]] and [[butyrylcholinesterase]] [[cholinesterase inhibitor|inhibitor]], and an [[irreversible inhibition|irreversible]] [[monoamine oxidase B]] [[enzyme inhibitor|inhibitor]], and combines the [[mechanism of action|mechanisms of action]] of older drugs like [[rivastigmine]] and [[rasagiline]] into a single molecule.<ref name="pmid19110207">{{cite journal  |vauthors=Weinreb O, Mandel S, Bar-Am O, etal | title = Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs | journal = Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics | volume = 6 | issue = 1 | pages = 163–74 |date=January 2009 | pmid = 19110207 | doi = 10.1016/j.nurt.2008.10.030 | url = http://linkinghub.elsevier.com/retrieve/pii/S1933-7213(08)00226-2}}</ref><ref name="pmid17017566">{{cite journal |vauthors=Weinstock M, Luques L, Bejar C, Shoham S | title = Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression | journal = Journal of Neural Transmission. Supplementum | volume = | issue = 70 | pages = 443–6 | year = 2006 | pmid = 17017566 | doi = | url = }}</ref> In addition to its neuroprotective properties, ladostigil enhances the expression of [[neurotrophic factor]]s like [[glial cell line-derived neurotrophic factor|GDNF]] and [[brain-derived neurotrophic factor|BDNF]], and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of [[neurogenesis]].<ref name="pmid18077571">{{cite journal |vauthors=Weinreb O, Amit T, Bar-Am O, Youdim MB | title = Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy | journal = Annals of the New York Academy of Sciences | volume = 1122 | issue = | pages = 155–68 |date=December 2007 | pmid = 18077571 | doi = 10.1196/annals.1403.011 | url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2007&volume=1122&spage=155}}</ref> Ladostigil also has [[antidepressant]] effects, and may be useful for treating comorbid [[Major depressive disorder|depression]] and [[anxiety]] often seen in such diseases as well.<ref name="pmid11889501">{{cite journal |vauthors=Weinstock M, Poltyrev T, Bejar C, Youdim MB | title = Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression | journal = Psychopharmacology | volume = 160 | issue = 3 | pages = 318–24 |date=March 2002 | pmid = 11889501 | doi = 10.1007/s00213-001-0978-x }}</ref><ref name="pmid12787840">{{cite journal |vauthors=Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M | title = A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease | journal = Progress in Neuro-psychopharmacology & Biological Psychiatry | volume = 27 | issue = 4 | pages = 555–61 |date=June 2003 | pmid = 12787840 | doi = 10.1016/S0278-5846(03)00053-8 | url = http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(03)00053-8}}</ref>

== See also ==
* [[Mofegiline]]
* [[Rasagiline]]
* [[Selegiline]]

== References ==
{{Reflist}}

{{Antioxidants}}
{{Nootropics}}
{{Acetylcholine metabolism and transport modulators}}
{{Monoamine metabolism modulators}}

[[Category:Acetylcholinesterase inhibitors]]
[[Category:Alkynes]]
[[Category:Carbamates]]
[[Category:Indanes]]
[[Category:Monoamine oxidase inhibitors]]